Discover open access scientific publications

Search, annotate, share and cite publications

Publications by W. Arafat

P3.01-03 the Cost Benefit From Second Line Immunotherapy in Metastatic NSCLC: ASCO Value Framework Prospective

Journal of Thoracic Oncology

Respiratory Medicine

English

Related publications

High TMB Predicts Immunotherapy Benefit in NSCLC

Cancer Discovery

English

P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-86 Treatment Outcomes With Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients With Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting

Journal of Oncology

English

P2.15-18 Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia

Journal of Thoracic Oncology

Respiratory Medicine

English

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

Value in Health

Occupational Health

English

P3.01-65 First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients With EGFR-Mutant Metastatic NSCLC Receiving TKIs

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-13 Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated With Immunotherapy and Ramucirumab Plus Docetaxel.

Journal of Thoracic Oncology

Respiratory Medicine

English